Marion David

Marion David

Auto-generated profile, based on publicly available information

Marion David

Kekkan Biologics Strasbourg France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
YCYue Cui
Yue Cui
MDMarion David
Marion David
LBLaura Bouchareychas
Laura Bouchareychas
SRSandrine Rouquier
Sandrine Rouquier
SSSatria Sajuthi
Satria Sajuthi
JGJulie Gertner-Dardenne
Julie Gertner-Dardenne
Regulatory T cells (Tregs) are key regulators in maintaining tissue homeostasis. Disrupted immune homeostasis is associated with Crohn’s disease (CD) pathogenesis. Thus, Treg therapy represents a promising long-acting treatment to restore immune balance in the diseased intestine. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized cancer treatment. This innovative approach also provides the opportunity to improve therapy for CD. By targeting a disease-relevant protein, interleukin-23 receptor (IL23R), we engineered Tregs expressing IL23R-CAR for treating active CD. Intestinal IL23R expression from active CD was verified by immunohistochemical analysis. Phenotypic and functional characteristics of IL23R-CAR Tregs were assessed using in vitro assays and their migration capacity was monitored in a xenograft tumor model. Transcriptomic and proteomic analyses were performed to associate molecular profiles with IL23R-CAR Treg activation against colon biopsy-derived cells from active CD patients. Our study showed that IL23R-CAR displayed negligible tonic signaling and a strong signal-to-noise ratio. IL23R-CAR Tregs maintained regulatory phenotype during in vitro expansion, even when chronically exposed to proinflammatory cytokines and target antigen. IL23R engagement on IL23R-CAR Tregs triggered CAR-specific activation and significantly enhanced their suppressive activity. Also, IL23R-CAR Tregs migrated to IL23R-expressing tissue in humanized mice. Finally, IL23R-CAR Tregs elicited a specific activation against colon biopsy-derived cells from active CD, suggesting an efficient CAR engagement in active CD. Molecular profiling of CD patient biopsies also revealed transcriptomic and proteomic patterns associated with IL23R-CAR activation. Overall, our results demonstrate that IL23R-CAR Tregs represent a promising therapy for active CD.

30 July 2019
Verified
Book Chapter
Closed access
PDF file
MDMarion David
Marion David
MLMaarten Loopmans
Maarten Loopmans
Belgium, a small multicultural country, has always been influenced by neighboring powers, including in its approach to prostitution. Culturally, Belgium has a similar, permissive view toward prostitution as the Netherlands. Considering prostitution to be "sexual exploitation", Belgian feminism groups are against the decriminalization of procuring or legalization of commercial sex, and are increasingly pleading for the criminalization of clients in accordance with the Swedish model. Advertising of prostitution is also penalized, as the Law of March 27, 1995 punishes soliciting through all possible sources of communication. The main purpose of the 1995 legal changes was to define human trafficking for sexual exploitation as a separate offense. The policy focus on trafficking has in Belgium, even more than in other European countries, determined public debates on commercial sex. The highly varied policy approaches to window prostitution have had different effects on the ground.

12 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MDMarion David
Marion David
Phillip SchielePhillip Schiele
Phillip Schiele
DMDavide Monteferrario
Davide Monteferrario
GSGaëlle Saviane
Gaëlle Saviane
AMAngélique E. Martelli
Angélique E. Martelli
DFDavid Fenard
David Fenard
CAR-T therapies have shown remarkable success in treating hematological malignancies. However, effectiveness against solid tumors remains limited due to the immunosuppressive tumor microenvironment (TME), such as TGF-β signaling and upregulated immune checkpoints (ICs). Furthermore, identifying universal, tumor-specific targets for CAR-T cells in solid tumors is challenging, but using reinvigorated, immunosuppressive-resistant tumor-infiltrating lymphocytes (TILs) could be a promising alternative approach. Unlike nucleases, which may induce genotoxic DNA double-strand breaks, multiplexed Zinc Finger Repressors (ZFR) offer a safer alternative for knocking out TME-related immunosuppressive factors. We epigenetically repressed PD-1 expression both in CAR-T cells and TILs from colorectal liver metastases. PD-1 repression did not affect T cell viability, proliferation, or functionality. In a murine B cell lymphoma model, PD-1-repressed CD19-CAR-T cells exhibited enhanced anti-tumor activity and improved survival. Notably, PD-1 repression alone did not increase cytotoxicity against a PD-L1-positive colorectal cell line in vitro. To further increase anti-tumor potency in this context, ZFR-expressing lentiviral vectors targeting PD-1 and other ICs (LAG-3, TIM-3, TIGIT) or TGFBR2 were developed, improving significantly the cytotoxic activity in TILs. This strategy highlights the potential to enhance tumor-reactive T cells and improve anti-cancer immunotherapies by epigenetically repressing immunosuppressive factors in the TME using multiplexed ZFRs.

20 October 2026 in Molecular Oncology
Verified
Journal Article
Open access
MDMarion David
Marion David
AKArthur Karaulic
Arthur Karaulic
ABAudrey Bennetot
Audrey Bennetot
CFClémence Fournier
Clémence Fournier
QOQuentin Odet
Quentin Odet
GPGilles Pagès
Gilles Pagès
Angiogenesis is a major driver of tumor progression and a validated therapeutic target in highly vascularized cancers such as clear cell renal cell carcinoma. However, the clinical benefit of antivascular endothelial growth factor therapies is limited by the emergence of resistance. We identified a vascular endothelial growth factor A splice variant, termed Lymphatic and Vascular Resistance Factor (LVRF), which promotes both angiogenesis and lymphangiogenesis and is upregulated following anti‐angiogenic treatment. To therapeutically target this pathway, we generated fully human monoclonal antibodies against LVRF. Lead antibodies displayed high specificity and nanomolar affinity and effectively inhibited LVRF‐driven biological activities. Anti‐LVRF antibodies reduced renal carcinoma cell invasion, inhibited vascular and lymphatic endothelial responses, and suppressed lymphatic endothelial cell sprouting. In vivo , treatment significantly reduced the growth of bevacizumab‐resistant renal carcinoma xenografts, induced regression of blood and lymphatic vessels, and decreased metastatic dissemination in zebrafish models. These findings identify LVRF as a mediator of resistance to anti‐angiogenic therapy and support therapeutic targeting of LVRF as a novel strategy for vascularized tumors resistant to current antivascular endothelial growth factor treatments.

31 March 2026
Verified
Thesis
Closed access
MDMarion David
Marion David
Les métastases sont des conséquences dramatiques lors de la progression des cancers. Malgré les traitements actuels la médiane de survie de patients atteints de métastases osseuses n’est que de 24 mois. Donc l’identification de nouvelles cibles thérapeutiques dans le traitement ou la prévention des métastases revêt un caractère crucial. L’objectif de ce travail de thèse est d’étudier le rôle de l’acide lysophosphatidique (LPA) et de l’autotaxine (ATX) dans la dissémination métastatique des cancers du sein. Notre laboratoire a montré que le LPA contrôle la croissance tumorale et la progression des métastases osseuses dans le contexte des cancers du sein. On sait depuis peu qu’en raison de son activité lysophospholipase D, ATX produit du LPA à partir de la lysophosphatidylcholine et contrôle les niveaux de LPA dans la circulation sanguine. ATX est une protéine sécrétée présentant des propriétés métastatiques. Les travaux présentés dans cette thèse montrent que l'expression d'ATX par les cellules tumorales contrôle les événements précoces de la dissémination métastatique des cancers du sein ainsi que le processus plus tardif de formation et de progression des métastases osseuses en agissant sur la fonction ostéoclastique. Il existe un grand nombre de récepteurs capables de transmettre l’activation cellulaire par le LPA (LPA1-6). Ce travail de thèse montre également que le niveau d’expression du récepteur LPA1 au niveau de la tumeur primaire est un facteur prédictif de la rechute métastatique chez les patientes ayant un cancer du sein. D’autre part dans un modèle animal préclinique, nous avons observé que le ciblage thérapeutique précoce de LPA1 par le DEBIO-0719 bloque efficacement la dissémination métastatique des cellules de cancer du sein. En conclusion, nos résultats montrent que le ciblage de l’axe ATX/LPA/LPA1 présente un haut potentiel thérapeutique chez des patientes atteintes d’un cancer du sein à fort risque métastatique